When it's time to talk with your doctor about primary progressive multiple sclerosis (PPMS), you may not know where to begin. Discover 11 important questions you can ask to get the conversation ...

Misconceptions about primary progressive multiple sclerosis (PPMS) are common, especially since the condition can look different for everyone. Knowing what’s true (and what’s not) can help you ...

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that ...

Background Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

In 2017, the U.S. Food and Drug Administration (FDA) approved ocrelizumab (Ocrevus) to treat adults who have relapsing forms of multiple sclerosis and primary-progressive multiple sclerosis (PPMS ...

Roche’s first ever treatment for people with a highly debilitating form of multiple sclerosis is too expensive for the NHS, NICE has ruled in a preliminary decision.

The progression of multiple sclerosis can be unpredictable, as some individuals show mild symptoms while others show varying ...

Roche is running three late-stage studies, namely FENhance 1 and 2 trials in relapsing MS, comparing the drug to Sanofi's Aubagio (teriflunomide) and the FENtrepid trial in primary progressive MS ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced ...

Further analyses by disease subtype showed that vidofludimus calcium was associated with a 33% reduction in 24wCDW in the primary progressive multiple sclerosis (PPMS) study population (n=152 ...